Discontinued — last reported Q4 '25
Edwards Lifesciences Other Non-Current Liabilities decreased by 3.2% to $350.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.9%, from $357.60M to $350.70M. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 7.5% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Significant changes may reflect shifts in lease accounting, changes in employee benefit plans, or the emergence of long-term legal risks.
A catch-all category for long-term obligations that do not fall into major classifications like debt or deferred taxes....
Varies significantly by industry; companies with large physical retail footprints often show higher values here due to long-term leases.
other_non_current_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $268.40M | $275.50M | $267.30M | $259.70M | $222.20M | $221.10M | $217.50M | $260.10M | $242.70M | $240.30M | $264.30M | $266.50M | $257.10M | $322.60M | $357.50M | $357.60M | $379.20M | $362.60M | $362.30M | $350.70M |
| QoQ Change | — | +2.6% | -3.0% | -2.8% | -14.4% | -0.5% | -1.6% | +19.6% | -6.7% | -1.0% | +10.0% | +0.8% | -3.5% | +25.5% | +10.8% | +0.0% | +6.0% | -4.4% | -0.1% | -3.2% |
| YoY Change | — | — | — | — | -17.2% | -19.7% | -18.6% | +0.2% | +9.2% | +8.7% | +21.5% | +2.5% | +5.9% | +34.2% | +35.3% | +34.2% | +47.5% | +12.4% | +1.3% | -1.9% |